NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
MOMA Therapeutics
Boston Scientific Corporation
Varian, a Siemens Healthineers Company
Bristol-Myers Squibb
Linnaeus Therapeutics, Inc.